FAQ: Oncotelic Therapeutics and Sapu Bioscience's Landmark Review on Sub-15 nm Nanoparticles for Drug Delivery

What is the main topic of the published review article?

The review article comprehensively examines nanoparticles exclusively within the 5-15 nm range, defining this emerging scale as a new frontier in drug delivery that could redefine nanomedicine.

Why are sub-15 nm nanoparticles considered significant for drug delivery?

These nanoparticles achieve deeper tissue penetration, reduced organ accumulation, faster renal clearance, and enhanced diffusion across biological barriers including the blood-brain barrier, overcoming delivery and toxicity limitations of both small molecules and larger nanocarriers.

Who are the companies involved in this publication?

Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and their joint venture partner Sapu Bioscience collaborated on this landmark review article.

Where was this review article published?

The article was published in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842) and is available at https://doi.org/10.3390/ijms262210842.

What specific advantages do sub-15 nm nanoparticles offer over other drug delivery systems?

They provide superior tissue penetration, reduced organ accumulation, faster clearance from the body, and better diffusion across biological barriers compared to both small molecules and larger nanocarriers.

Who were the authors of this review article?

The paper was authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and Cynthia Lee.

What is Oncotelic Therapeutics’ primary focus as a company?

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oncology and immunotherapy products, particularly for high-unmet-need cancers and rare pediatric indications.

How can investors stay updated on Oncotelic Therapeutics news?

The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC.

What makes this review article unique in the field of nanomedicine?

This is the first comprehensive review to examine nanoparticles exclusively within the 5-15 nm range, establishing this size regime as a new pharmacological paradigm for drug delivery.

What is Oncotelic’s involvement in joint ventures and partnerships?

Beyond its internal programs, Oncotelic licenses and codevelops drug candidates through joint ventures, including owning 45% of GMP Bio, a joint venture advancing complementary drug candidates in oncology and rare disease therapeutics.